kwic
function
function
right
off
ON
392
1
100
500
strict
ELIZA cgi-bash version rev. 1.91
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for function out of >500 occurrences
288503 occurrences (No.86 in the rank) during 5 years in the PubMed. [cache]
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to function]
288503 occurrences (No.86 in the rank) during 5 years in the PubMed. [cache]
| 392) In pharmacogenomics, variable receptor phenotypes, resulting from genetic polymorphisms, are often described as a change in protein function or regulation observed upon exposure to a drug. |
| PMID:33395026 DOI:10.1097/FPC.0000000000000424 |
| 2021 Pharmacogenetics and genomics |
| * Ligand-specific pharmacogenetic effects of nonsynonymous mutations. |
| - In pharmacogenomics, variable receptor phenotypes, resulting from genetic polymorphisms, are often described as a change in protein function or regulation observed upon exposure to a drug. However, in some instances, phenotypes are defined using a class of medications rather than individual drugs. This paradigm assumes that a variation associated with a drug response phenotype will retain the magnitude and direction of the effect for other drugs with the same mechanism of action. However, nonsynonymous polymorphisms may have ligand-specific effects. The purpose of this study was to investigate the potential for point mutations to asymmetrically affect the binding of different drugs to a common target. Ligand binding data from site-directed mutagenesis studies on five G-protein coupled receptors (beta-1 and -2 adrenergic, dopamine D2, angiotensin II and mu-opioid receptor) were collected and analyzed. Binding data from 81 studies for 253 ligands with 447 mutant proteins, including 10 naturally occurring human variants, were analyzed, yielding 1989 mutation-ligand pairs. Fold change in binding affinity for mutant proteins, relative to the wild-type, for different drugs was examined for ligand-specific effects, with a fold-change difference of one or more orders of magnitude between agents considered significant. Of the mutations examined, 49% were associated with ligand-specific effects. One human variant (T164I, beta-2 adrenergic receptor) showed ligand-specific effects for antiasthmatic agents. These results indicate that ligand-specific changes in binding are a possible consequence of missense mutations. This implies that caution needs to be exercised when grouping drugs together during design or interpretation of genotype-phenotype association studies. |
[
right
kwic]
| (1)86 *null* | (9)5  following |
(17)3 mutations |
(25)2 for |
| (2)72 of |
(10)5 was |
(18)3 not |
(26)2 have |
| (3)68 and |
(11)5 with |
(19)3 were |
(27)2 including |
| (4)63 in |
(12)4 by |
(20)3 which |
(28)2 measures |
| (5)16 is |
(13)4 has |
(21)2 after |
(29)2 or |
| (6)13 as |
(14)4 tests |
(22)2 among |
(30)2 quality |
| (7)5 are |
(15)4 to |
(23)2 data |
(31)2 that |
| (8)5 associated |
(16)3 at |
(24)2 during |
(32)2 variants |
add keyword
--- WordNet output for function ---